Apricus Biosciences, Inc [APRI] to Ring The NASDAQ Stock Market Closing Bell
March 08 2012 - 9:40AM
ADVISORY, March 8, 2012 (GLOBE NEWSWIRE) --
What:
Apricus Biosciences, Inc [APRI], a San Diego-based,
revenue-generating specialty pharmaceutical company, will visit the
NASDAQ MarketSite in Times Square.
In honor of the occasion, Dr. Bassam Damaj, Chairman, President
and Chief Executive Officer will ring the Closing Bell.
Where:
NASDAQ MarketSite – 4 Times Square – 43rd & Broadway –
Broadcast Studio
When:
Friday, March 9th, 2012 – 3:45 p.m. to 4:00 p.m.
ET
Contact: Jack Wynn Public
Affairs Director, Washington, D.C. (703) 623-4288
jackwynn@comcast.net
NASDAQ MarketSite: Jen Knapp (212) 401-8916
Jennifer.knapp@nasdaqomx.com
Feed Information:
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC
3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
Facebook and Twitter:
For multimedia features such as exclusive content, photo
postings, status updates and video of bell ceremonies please visit
our Facebook page at:
http://www.facebook.com/#!/NASDAQ.
For news tweets, please visit our Twitter page at:
http://twitter.com/nasdaqomx
Webcast:
A live webcast of the NASDAQ Closing Bell will be available at:
http://www.nasdaq.com/about/marketsitetowervideo.asx or
http://social.nasdaqomx.com.
Photos:
To obtain a hi-resolution photograph of the Market Close, please
go to http://www.nasdaq.com/reference/marketsite_events.stm and
click on the market close of your choice.
About Apricus Biosciences, Inc
[APRI]:
Apricus Bio is a San Diego-based revenue-generating specialty
pharmaceutical company, with commercial products and a broad
pipeline across numerous therapeutic classes.
Revenues and growth are driven from the sales of the Company's
commercial products through its Apricus Pharmaceuticals USA, Inc.
and NexMed (USA), Inc. subsidiaries and through out-licensing in
certain territories of its product pipeline and NexACT®
technology.
Apricus Bio currently markets Totect® (dexrazoxane HCl), the
only drug approved in the US for the treatment of anthracycline
extravasation. The Company also plans to market in 2012 in the U.S.
or certain other countries the following products: (a)
Granisol® (granisetron HCI) oral solution, the only FDA-approved,
oral, ready-to-use liquid solution of granisetron, (b) Aquoral™, an
FDA-cleared, prescription-only spray for the treatment of
Xerostomia (the medical term for dry mouth due to a lack of saliva)
and (c) NitroMist® (nitroglycerin sublingual spray), an
FDA-approved nitrate vasodilator indicated for acute relief of an
attack or acute prophylaxis of angina pectoris (chest pain) due to
coronary artery disease (narrowing of the blood vessels that supply
blood to the heart).
Apricus Bio's current NexACT® pipeline includes Vitaros®,
approved in Canada for the treatment of erectile dysfunction, as
well as compounds in development from pre-clinical through
pre-registration currently focused on Sexual Dysfunction, Oncology,
Dermatology, Autoimmune, Pain, Anti-Infectives, Diabetes and
Consumer Healthcare.
The Company also expects to develop and/or acquire and then
bring to market additional pharmaceutical products in areas of care
that will benefit patient needs worldwide.
For further information on Apricus Bio, visit
http://www.apricusbio.com, and for information on its subsidiary
please visit http://www.nexmedusa.com. You can also receive
information at http://twitter.com/apricusbio.
About NASDAQ OMX:
The NASDAQ OMX Group, Inc. is the world's largest exchange
company. It delivers trading, exchange technology and public
company services across six continents, with more than 3,500 listed
companies. NASDAQ OMX offers multiple capital raising solutions to
companies around the globe, including its U.S. listings market,
NASDAQ OMX Nordic, NASDAQ OMX Baltic, NASDAQ OMX first North, and
the U.S. 144A sector. The company offers trading across multiple
asset classes including equities, derivatives, debt, commodities,
structured products and exchange-traded funds. NASDAQ OMX
technology supports the operations of over 70 exchanges, clearing
organizations and central securities depositories in more than 50
countries. NASDAQ OMX Nordic and NASDAQ OMX Baltic are not
legal entities but describe the common offering from NASDAQ OMX
exchanges in Helsinki, Copenhagen, Stockholm, Iceland, Tallinn,
Riga, and Vilnius. For more information about NASDAQ OMX, visit
http://www.nasdaqomx.com. *Please follow NASDAQ OMX on Facebook
(http://www.facebook.com/#!/NASDAQ) and Twitter
(http://www.twitter.com/nasdaqomx).
NDAQA
Nasdaq (NASDAQ:NDAQ)
Historical Stock Chart
From Apr 2024 to May 2024
Nasdaq (NASDAQ:NDAQ)
Historical Stock Chart
From May 2023 to May 2024